These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 36848181)

  • 1. Challenges and optimal strategies of CAR T therapy for hematological malignancies.
    Zhang Y; Xu Y; Dang X; Zhu Z; Qian W; Liang A; Han W
    Chin Med J (Engl); 2023 Feb; 136(3):269-279. PubMed ID: 36848181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.
    Sun W; Jiang Z; Jiang W; Yang R
    Cancer Treat Res Commun; 2022; 33():100638. PubMed ID: 36184307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
    Holstein SA; Lunning MA
    Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR-T cell therapy: current limitations and potential strategies.
    Sterner RC; Sterner RM
    Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
    El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
    Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in CAR-T-cell therapy in T-cell malignancies.
    Zheng R; Zhu X; Xiao Y
    J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T Cell Therapy for Hematological Malignancies.
    Yang X; Wang GX; Zhou JF
    Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies.
    Huang J; Huang X; Huang J
    Front Immunol; 2022; 13():1019115. PubMed ID: 36248810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR-NK for tumor immunotherapy: Clinical transformation and future prospects.
    Wang W; Jiang J; Wu C
    Cancer Lett; 2020 Mar; 472():175-180. PubMed ID: 31790761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of CAR T cell in malignancies: A scoping review.
    Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
    Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
    Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
    BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of CRISPR/Cas9 System and CAR-T Cell Therapy: A New Era for Refractory and Relapsed Hematological Malignancies.
    Hu KJ; Yin ETS; Hu YX; Huang H
    Curr Med Sci; 2021 Jun; 41(3):420-430. PubMed ID: 34218353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Khan AN; Asija S; Pendhari J; Purwar R
    Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes.
    Roselli E; Faramand R; Davila ML
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33463538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
    Tang L; Zhang Y; Hu Y; Mei H
    Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-T treatment for hematological malignancies.
    Atrash S; Bano K; Harrison B; Abdallah AO
    J Investig Med; 2020 Jun; 68(5):956-964. PubMed ID: 32200355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies.
    Gao X; Liu J; Sun R; Zhang J; Cao X; Zhang Y; Zhao M
    Ann Hematol; 2024 Aug; 103(8):2569-2589. PubMed ID: 37853078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.